Anticancer Drugs
- MA L, Zhao X, Lu X, Shen J, et al
KLF4 activates LATS2 to promote cisplatin sensitivity in ovarian cancer through
DNA damage.
Anticancer Drugs. 2024 Sep 27. doi: 10.1097/CAD.0000000000001662.
BMC Cancer
- SHUANG T, Wu S, Zhao Y, Yang Y, et al
The up-regulation of PAK2 indicates unfavorable prognosis in patients with serous
epithelial ovarian cancer and contributes to paclitaxel resistance in ovarian
cancer cells.
BMC Cancer. 2024;24:1213.
Gynecol Oncol
- CARUSO G, Langstraat CL, Kumar A, McGree ME, et al
Textbook oncologic outcome is an easy-to-use composite quality measure that is
strongly associated with survival in advanced-stage ovarian cancer.
Gynecol Oncol. 2024;191:86-94.
- LIAO JB, Jejurikar NS, Hitchcock-Bernhardt KM, Gwin WR, et al
Intraperitoneal immunotherapy with denileukin diftitox (ONTAK) in recurrent
refractory ovarian cancer.
Gynecol Oncol. 2024;191:74-79.
J Clin Oncol
- LEE JM, Brady MF, Miller A, Moore RG, et al
Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or
Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer:
NRG-GY005.
J Clin Oncol. 2024 Oct 3:JCO2400683. doi: 10.1200/JCO.24.00683.
Lancet Oncol
- SUNDAR S, Agarwal R, Davenport C, Scandrett K, et al
Risk-prediction models in postmenopausal patients with symptoms of suspected
ovarian cancer in the UK (ROCkeTS): a multicentre, prospective diagnostic
accuracy study.
Lancet Oncol. 2024;25:1371-1386.
- TASKIRAN C, Canturk MM
Diagnostic accuracy of risk prediction models in postmenopausal patients with
suspected ovarian cancer.
Lancet Oncol. 2024;25:1251-1252.
- PENG Z, Li H, Gao Y, Sun L, et al
Sintilimab combined with bevacizumab in relapsed or persistent ovarian clear cell
carcinoma (INOVA): a multicentre, single-arm, phase 2 trial.
Lancet Oncol. 2024;25:1288-1297.
Free Medical Abstracts
Privacy Policy
Sponsors
Share
© Amedeo 1997-2016